Skip to main content

Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice: A Retrospective Cohort Study

    Basic Details
    Medical Product
    Health Outcome(s)
    atrial fibrillation
    extracranial bleeding
    intracranial hemorrhage
    ischemic stroke
    myocardial infarction

    Dabigatran (150 mg twice daily) has been associated with lower rates of stroke than warfarin in trials of atrial fibrillation, but large-scale evaluations in clinical practice are limited. The authors of this article compared incidence of stroke, bleeding, and myocardial infarction in patients receiving dabigatran versus warfarin in practice. The authors found that in matched adults with atrial fibrillation treated in practice, the incidences of stroke and bleeding with dabigatran versus warfarin were consistent with those seen in trials. The possible relationship between dabigatran and myocardial infarction warrants further investigation.

    Time Period
    2010 - 2014
    Population / Cohort
    All individuals 18 years of age or older

    Alan S. Go MD, Daniel E. Singer MD, Sengwee Toh ScD, T. Craig Cheetham PharmD, MS, Marsha E. Reichman PhD, David J. Graham MD, MPH, Mary Ross Southworth PharmD, Rongmei Zhang PhD, Rima Izem PhD, Margie R. Goulding PhD, Monika Houstoun PharmD, Katrina Mott MS, Sue Hee Sung MPH, Joshua J. Gagne PharmD, ScD